Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy

Pia Baumann; Jan Nyman; Morten Høyer; Berit Wennberg; Giovanna Gagliardi; Ingmar Lax; Ninni Drugge; Lars Ekberg; Signe Friesland; Karl-Axel Johansson; Jo‐Åsmund Lund; Elisabeth Morhed; Kristina Nilsson; Nina Jackson Levin; Merete Paludan; Christer Sederholm; Anders Traberg; Lena Wittgren; Rolf Lewensohn

doi:10.1200/jco.2008.21.5681

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

With a 3-year local tumor control rate higher than 90% with limited toxicity, SBRT emerges as state-of-the-art treatment for medically inoperable stage I NSCLC and may even challenge surgery in operable instances.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Baumann et al. (2009) studied this question.

synapsesocial.com/papers/69dc7c1524e766dc31359469 https://doi.org/10.1200/jco.2008.21.5681

View Full Paper

Ask AI

Bookmark

Share

Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy

Ask about this paper

Abstract

Discussion

Cite This Study

Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading